{"id":70173,"date":"2026-07-17T21:39:38","date_gmt":"2026-07-17T13:39:38","guid":{"rendered":"https:\/\/flcube.com\/?p=70173"},"modified":"2026-07-17T21:39:39","modified_gmt":"2026-07-17T13:39:39","slug":"sichuan-biokins-yizekang-receives-nmpa-approval-as-worlds-first-egfrxher3-bispecific-adc-for-esophageal-squamous-cell-carcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70173","title":{"rendered":"Sichuan Biokin&#8217;s Yizekang Receives NMPA Approval as World&#8217;s First EGFR\u00d7HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sichuan Biokin Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA: 688506<\/a>) announced that China&#8217;s National Medical Products Administration (NMPA) has approved <strong>Yizekang<\/strong> (izalontamab brengitecan\/iza-bren) for a new indication in adult patients with relapsed\/metastatic esophageal squamous cell carcinoma (ESCC) who have failed prior treatment with PD-1\/PD-L1 inhibitors in combination with platinum-based chemotherapy. Iza-bren represents the <strong>world&#8217;s first approved EGFR\u00d7HER3 bispecific antibody-drug conjugate<\/strong> (ADC).<\/p>\n\n\n\n<h2 id=\"h-regulatory-approval-summary\" class=\"wp-block-heading\">Regulatory Approval Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>China National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Yizekang (izalontamab brengitecan\/iza-bren)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Full approval for new indication<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Relapsed\/metastatic esophageal squamous cell carcinoma (ESCC)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adults who failed PD-1\/PD-L1 inhibitors + platinum-based chemotherapy<\/td><\/tr><tr><td><strong>Innovation Status<\/strong><\/td><td>World&#8217;s first EGFR\u00d7HER3 bispecific ADC<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>First-in-class (FIC) Class 1 therapeutic biologic<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-mechanism\" class=\"wp-block-heading\">Product Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> Bispecific antibody-drug conjugate (ADC)<\/li>\n\n\n\n<li><strong>Targets:<\/strong> Dual targeting of EGFR and HER3 receptors<\/li>\n\n\n\n<li><strong>Payload:<\/strong> Cytotoxic agent delivered specifically to tumor cells expressing both targets<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Simultaneous blockade of two key oncogenic pathways enhances anti-tumor activity and overcomes resistance mechanisms<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Protected by composition-of-matter and method-of-use patents extending to 2042+<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-timeline-amp-pipeline-progression\" class=\"wp-block-heading\">Regulatory Timeline &amp; Pipeline Progression<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Date<\/th><th>Indication<\/th><\/tr><\/thead><tbody><tr><td><strong>First Approval<\/strong><\/td><td>June 2026<\/td><td>Relapsed\/metastatic nasopharyngeal carcinoma (after \u22652 prior lines including PD-1\/PD-L1 inhibitors)<\/td><\/tr><tr><td><strong>Second Approval<\/strong><\/td><td>July 2026<\/td><td>Relapsed\/metastatic esophageal squamous cell carcinoma<\/td><\/tr><tr><td><strong>NDA Accepted<\/strong><\/td><td>Pending<\/td><td>Locally advanced or metastatic triple-negative breast cancer<\/td><\/tr><tr><td><strong>Future Development<\/strong><\/td><td>Ongoing<\/td><td>Additional solid tumor indications leveraging dual EGFR\u00d7HER3 targeting<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-context-amp-therapeutic-need\" class=\"wp-block-heading\">Market Context &amp; Therapeutic Need<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Esophageal Cancer Burden:<\/strong> China accounts for approximately 50% of global esophageal cancer cases, with ESCC representing 90% of cases in the region<\/li>\n\n\n\n<li><strong>Treatment Gap:<\/strong> Limited options for patients progressing after standard PD-1\/PD-L1 + chemotherapy regimens<\/li>\n\n\n\n<li><strong>Survival Challenge:<\/strong> Median overall survival in refractory ESCC typically less than 6 months<\/li>\n\n\n\n<li><strong>Target Expression:<\/strong> High co-expression of EGFR and HER3 in ESCC tumors provides strong rationale for bispecific approach<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-strategy-amp-market-impact\" class=\"wp-block-heading\">Commercial Strategy &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Population:<\/strong> Estimated 45,000+ ESCC patients annually in China eligible for third-line treatment<\/li>\n\n\n\n<li><strong>Pricing Position:<\/strong> Premium pricing expected given first-in-class status and significant unmet medical need<\/li>\n\n\n\n<li><strong>Reimbursement Pathway:<\/strong> Priority review designation supports accelerated inclusion in national reimbursement drug list (NRDL)<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Clinical trials planned for international markets following successful China launch<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, commercial expectations, and market opportunities for Yizekang. Actual results may differ due to risks including market adoption rates, competitive dynamics, reimbursement decisions, and international regulatory requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688506_20260717_BVEK.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688506_20260717_BVEK.\"><\/object><a id=\"wp-block-file--media-91bcf940-3a97-4308-bf6a-d97184aa6106\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688506_20260717_BVEK.pdf\">688506_20260717_BVEK<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688506_20260717_BVEK.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-91bcf940-3a97-4308-bf6a-d97184aa6106\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that China&#8217;s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[35,151,15,857],"class_list":["post-70173","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-biokin-pharmaceutical","tag-product-approvals","tag-sha-688506"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sichuan Biokin&#039;s Yizekang Receives NMPA Approval as World&#039;s First EGFR\u00d7HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that China&#039;s National Medical Products Administration (NMPA) has approved Yizekang (izalontamab brengitecan\/iza-bren) for a new indication in adult patients with relapsed\/metastatic esophageal squamous cell carcinoma (ESCC) who have failed prior treatment with PD-1\/PD-L1 inhibitors in combination with platinum-based chemotherapy. Iza-bren represents the world&#039;s first approved EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70173\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Biokin&#039;s Yizekang Receives NMPA Approval as World&#039;s First EGFR\u00d7HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma\" \/>\n<meta property=\"og:description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that China&#039;s National Medical Products Administration (NMPA) has approved Yizekang (izalontamab brengitecan\/iza-bren) for a new indication in adult patients with relapsed\/metastatic esophageal squamous cell carcinoma (ESCC) who have failed prior treatment with PD-1\/PD-L1 inhibitors in combination with platinum-based chemotherapy. Iza-bren represents the world&#039;s first approved EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70173\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-17T13:39:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-17T13:39:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70173#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70173\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Biokin&#8217;s Yizekang Receives NMPA Approval as World&#8217;s First EGFR\u00d7HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma\",\"datePublished\":\"2026-07-17T13:39:38+00:00\",\"dateModified\":\"2026-07-17T13:39:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70173\"},\"wordCount\":416,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"Product approvals\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70173#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70173\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70173\",\"name\":\"Sichuan Biokin's Yizekang Receives NMPA Approval as World's First EGFR\u00d7HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-17T13:39:38+00:00\",\"dateModified\":\"2026-07-17T13:39:39+00:00\",\"description\":\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that China's National Medical Products Administration (NMPA) has approved Yizekang (izalontamab brengitecan\\\/iza-bren) for a new indication in adult patients with relapsed\\\/metastatic esophageal squamous cell carcinoma (ESCC) who have failed prior treatment with PD-1\\\/PD-L1 inhibitors in combination with platinum-based chemotherapy. Iza-bren represents the world's first approved EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70173#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70173\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70173#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Biokin&#8217;s Yizekang Receives NMPA Approval as World&#8217;s First EGFR\u00d7HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Biokin's Yizekang Receives NMPA Approval as World's First EGFR\u00d7HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that China's National Medical Products Administration (NMPA) has approved Yizekang (izalontamab brengitecan\/iza-bren) for a new indication in adult patients with relapsed\/metastatic esophageal squamous cell carcinoma (ESCC) who have failed prior treatment with PD-1\/PD-L1 inhibitors in combination with platinum-based chemotherapy. Iza-bren represents the world's first approved EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70173","og_locale":"en_US","og_type":"article","og_title":"Sichuan Biokin's Yizekang Receives NMPA Approval as World's First EGFR\u00d7HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma","og_description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that China's National Medical Products Administration (NMPA) has approved Yizekang (izalontamab brengitecan\/iza-bren) for a new indication in adult patients with relapsed\/metastatic esophageal squamous cell carcinoma (ESCC) who have failed prior treatment with PD-1\/PD-L1 inhibitors in combination with platinum-based chemotherapy. Iza-bren represents the world's first approved EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC).","og_url":"https:\/\/flcube.com\/?p=70173","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-17T13:39:38+00:00","article_modified_time":"2026-07-17T13:39:39+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70173#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70173"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Biokin&#8217;s Yizekang Receives NMPA Approval as World&#8217;s First EGFR\u00d7HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma","datePublished":"2026-07-17T13:39:38+00:00","dateModified":"2026-07-17T13:39:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70173"},"wordCount":416,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Biokin Pharmaceutical","Product approvals","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70173#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70173","url":"https:\/\/flcube.com\/?p=70173","name":"Sichuan Biokin's Yizekang Receives NMPA Approval as World's First EGFR\u00d7HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-17T13:39:38+00:00","dateModified":"2026-07-17T13:39:39+00:00","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that China's National Medical Products Administration (NMPA) has approved Yizekang (izalontamab brengitecan\/iza-bren) for a new indication in adult patients with relapsed\/metastatic esophageal squamous cell carcinoma (ESCC) who have failed prior treatment with PD-1\/PD-L1 inhibitors in combination with platinum-based chemotherapy. Iza-bren represents the world's first approved EGFR\u00d7HER3 bispecific antibody-drug conjugate (ADC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70173#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70173"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70173#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Biokin&#8217;s Yizekang Receives NMPA Approval as World&#8217;s First EGFR\u00d7HER3 Bispecific ADC for Esophageal Squamous Cell Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70173"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70173\/revisions"}],"predecessor-version":[{"id":70175,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70173\/revisions\/70175"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}